scholarly journals Central sleep apnea: misunderstood and mistreated!

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 981 ◽  
Author(s):  
Jerome A. Dempsey

Central sleep apnea is prevalent in patients with heart failure, healthy individuals at high altitudes, and chronic opiate users and in the initiation of “mixed” (that is, central plus obstructive apneas). This brief review focuses on (a) the causes of repetitive, cyclical central apneas as mediated primarily through enhanced sensitivities in the respiratory control system and (b) treatment of central sleep apnea through modification of key components of neurochemical control as opposed to the current universal use of positive airway pressure.

2021 ◽  
Author(s):  
IMRAN HASAN IFTIKHAR ◽  
Rami N Khayat

Abstract Purpose: Adaptive servo-ventilation (ASV) is contraindicated for central sleep apnea (CSA) treatment in patients with heart failure with reduced ejection fraction (HFrEF) limiting treatment options. Though, continuous positive airway pressure (CPAP), bi-level PAP with back-up rate (BPAP-BUR) and transvenous phrenic nerve stimulation (TPNS) are alternatives, not much is known about their comparative efficacies, which formed the basis of this network meta-analysis, in which their effects on apnea hypopnea index (AHI) and subjective daytime sleepiness (based on Epworth sleepiness score (ESS)), were analyzed.Methods: PubMed was searched for potentially includable randomized controlled trials and network meta-analysis was conducted in R program using package netmeta.Results: Network meta-analysis showed no statistically significant differences between interventions in AHI reduction. In exploring heterogeneity, sensitivity analysis elicited statistically significant differences in AHI reduction between ASV and TPNS (-18.30 [-27.8; -8.79]), with BPAP-BUR (-21.90 [-30.79; -13.01]) and CPAP (-23.10 [-29.22; -16.98]), favoring ASV. Of all the interventions, only TPNS showed a statistically significant decrease in ESS (-3.70 (-5.58; -1.82)) when compared to guideline directed medical therapy (used as a common comparator across trials), while also showing significant differences when compared with ASV (-3.20 (-5.86; -0.54)), BPAP-BUR (-4.00 (-7.33; -0.68)), and CPAP (-4.45 (-7.75; -1.14)). Hasse diagram, accounting for both AHI and ESS as outcomes for relative hierarchy showed relative superiority of both ASV and TPNS over BPAP-BUR and CPAP.Conclusions: Results indicate relative superiority of TPNS and ASV to BPAP-BUR and CPAP in their effects on AHI and ESS reduction in patients with CSA and HFrEF.


Circulation ◽  
2007 ◽  
Vol 115 (25) ◽  
pp. 3173-3180 ◽  
Author(s):  
Michael Arzt ◽  
John S. Floras ◽  
Alexander G. Logan ◽  
R. John Kimoff ◽  
Frederic Series ◽  
...  

2005 ◽  
Vol 353 (19) ◽  
pp. 2025-2033 ◽  
Author(s):  
T. Douglas Bradley ◽  
Alexander G. Logan ◽  
R. John Kimoff ◽  
Frédéric Sériès ◽  
Debra Morrison ◽  
...  

2014 ◽  
Vol 10 (1) ◽  
pp. 57 ◽  
Author(s):  
Roopika Reddy, MD ◽  
David Adamo, RPSGT ◽  
Thomas Kufel, MD ◽  
Jahan Porhomayon, MD ◽  
Ali A. El-Solh, MD, MPH

Objective: To systematically review the various modalities of positive airway pressure (PAP) in the treatment of opioid-related central sleep apnea (CSA).Design: Systematic review.Interventions: MEDLINE, the Cochrane Library, and EMBASE were screened through March 2013 to identify articles which investigated treatment of opioid-related CSA with PAP. Eligible articles were identified in a staged process and were assessed by two investigators independently. The methodological quality of the reporting of eligible articles was assessed using a set of questions addressing both general and statistical methodologies.Results: Five articles met the inclusion criteria for a total of 127 patients. All patients had been on opioids for at least 6 months. The dose ranged from 10 mg to 450 mg daily of morphine equivalent dose. Continuous positive airway pressure (CPAP) was proven mostly ineffective in reducing central apneic events. Bilevel positive airway pressure (BiPAP) with and without supplemental oxygen achieved elimination of central apneas in 62 percent of patients. Adaptive servo ventilation (ASV) yielded conflicting results with 58 percent of participants attaining a central apnea index <10 per hour. The presence of ataxic breathing predicted poor response to PAP.Conclusions: The available evidence on the efficacy of PAP in opioid-related CSA is inconclusive. With the increasing use of opioids, further studies are needed to assess optimal PAP therapy and predictors of success in this group of patients.


CHEST Journal ◽  
2008 ◽  
Vol 133 (3) ◽  
pp. 690-696 ◽  
Author(s):  
Takatoshi Kasai ◽  
Koji Narui ◽  
Tomotaka Dohi ◽  
Naotake Yanagisawa ◽  
Sugao Ishiwata ◽  
...  

CHEST Journal ◽  
2008 ◽  
Vol 134 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Michael Arzt ◽  
Roland Wensel ◽  
Sylvia Montalvan ◽  
Thomas Schichtl ◽  
Stephan Schroll ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document